Estradiol, Progesterone and Testosterone Therapies for Women

The Importance of Route of Delivery

Swallowing any hormone or hormone-like drug means that the entire dose must pass first through

the liver, the primary organ of our biochemical metabolism. This causes 2 problems not seen with

transdermal or parenteral delivery (e.g. subcutaneous injections and pellets): the hormone has an

excessive effect on the liver and the liver has an excessive effect on the hormone; usually metabolizing it

into other molecules, possibly rendering it completely ineffective (e.g. oral testosterone and

progesterone). In general, the evidence supports transdermal or parenteral replacement over oral

replacement for most steroid hormones, and for estradiol and testosterone in particular.1 Higher

estradiol levels in the serum have a small pro-clotting effect. Oral estrogens in particular overdose the

liver, increasing its production clotting factor proteins. This can promote deep vein thrombosis,

pulmonary embolus, heart attack or stroke. Unlike oral estrogens, including oral estrogens, including

oral estardiol, transdermal estradiol does not significantly increase markers of blood clotting risk ,2 or risk

of thrombosis.3 The risk of venous thromboembolic disease is 4 times greater with oral estrogens than

with transdermal estradiol. 4 In a large Danish cohort study, transdermal estradiol reduced heart attack

risk by 40%, whereas no benefit was seen with oral estrogens.5

Estradiol also causes the liver to make several hormone-binding proteins, oral estradiol therapy

exagerates this effect, causing the liver to make 2 times more sex-hormone binding globulin, and

reducing free testosterone levels by half.6 Transdermal estradiol has only a minimal effect on SHBG

levels.7 Oral Premarin produces large increases in thyroid-binding globulin, cortisol binding-globulin and

sex-hormone binding globulin and decreases in free testosterone, while transdermal estradiol produces

minimal changes.8 Oral estradiol increases activated protein C resistance, a marker for thrombotic risk,

whereas transdermal estradiol does not.9 Oral estradiol increases C-reactive protein, a marker of

inflammation, transdermal estradiol does not.10 Transdermal estradiol lowers blood pressure whereas

oral CEE does not.11 Oral CEE reduces insulin sensitivity while transdermal estradiol improves insulin

sensitivity12 and thereby helps prevent diabetes mellitus. Oral CEE and higher doses of oral estradiol

increase the risk of gallbladder disease and cholecystectomy;13 transdermal estradiol does not.14 Oral

estradiol is excessively metabolized by the liver into estrone, producing levels that are much higher than

normal. All oral estrogens, even bioidentical estradiol, should be avoided. For a summary of known

differences between oral estrogen—of all kinds—and trandermal estradiol, see Fig. 14. IGF-1 mediates

many of the effects of growth hormone in the body. Oral CEE reduces hepatic IGF-1 production and

serum IGF-1levels, whereas trandsdermal estradiol increases IGF-1 levels.15

Oral progesterone is almost completely metabolized by liver and inactivated. To get around this

problem, Prometrium was developed and approved by the FDA in 1998. It delivers progesterone in a

capsule filled with peanut oil to increase absorption by passing into the intestinal lymphatic system,

bypassing the liver and entering the venous circulation directly. However, this is only partially effective

and most progesterone is still metabolized in the liver, producing high levels of metabolites and greatly

reducing the effectiveness of the capsule. The metabolites are measured as progesterone using non-

specific immunoassay techniques, creating the false impression of high progesterone delivery. Only

about 1/8th of the serum level measured is actually progesterone.16 Only liquid-chromatography-mass

spectroscopy (LC-MS) can identify specific progesterone and other molecules. The metabolites can also

produce drowsiness, flushing and nausea. The sedating effect can help with sleep if the capsule is taken

at bedtime, but may leave residual sedation in the morning. Oral progesterone is quite ineffective—it

cannot be used for luteal phase support in infertility treatments. Vaginal progesterone is much more

effective for this purpose even though it produces much lower serum levels.17 What is measured with

transdermal or vaginal delivery is mostly progesterone. When

progesterone is measured in whole blood with LC/MS, only 80mg

of progesterone applied to the skin produces the same 24hr whole

blood progesterone levels as 200mg of oral Prometrium.18

Fortunately, Prometrium and its generics will dissolve when

inserted vaginally at bedtime, providing much greater uterine and

systemic effect.

How to Restore Estradiol and Progesterone

The practice of BHRT for menopause is not monolithic. There are different schools of thought

regarding how to test hormone levels, by what routes to deliver the hormones (oral, sublingual,

transdermal, pellets, etc.), what hormone levels to achieve, and whether it is necessary to induce a

withdrawal bleed (period) every month. Some BHRT practitioners rely solely on saliva tests to assess

hormone levels, others use blood tests. What BHRT practitioners do generally agree upon is that they

will prescribe only bioidentical molecules, they will prescribe progesterone to all women, and they

believe that a woman should continue estradiol-progesterone replacement for life. I will provide my

own assessment of these issues based upon the scientific literature and personal experience.

Symptoms

The preliminary assessment of any woman includes taking a history, gathering of current symptoms

and then testing to measure hormone levels. Since it takes a significant estradiol production to produce

uterine bleeding, Symptoms occurring in a woman who is menstruating regularly are unlikely to be due

to estradiol deficiency—although this is not always true. Hot flashes are the one symptom that most

often causes a woman to seek hormone replacement. These can also be due to cortisol deficiency and to

thyroid deficiency or excess. If the woman is perimenopausal or menopausal and estradiol levels are

low, I will always give them a trial of estradiol-progesterone therapy first to see if it eliminates the hot

flashes. Vaginal dryness is a cardinal symptom of estradiol deficiency and is reliably resolved with

replacement. I inquire about breast symptoms. Low estrogen levels will cause the breasts to feel soft

and non-tender at all times, whereas episodes of breast fullness suggest that estradiol is being produced

at times. Low estradiol levels can cause night sweats and/or poor sleep quality with frequent

awakenings. It is difficult to fall back asleep. Low estradiol levels can cause a subtle depression and

irritability also. On the other hand, if a woman has symptoms of high estradiol levels with inadequate

Indications for Progesterone Irregular menstrual cycles No periods—amenorrheaHeavy bleedingFibrocystic breast diseaseEndometriosis/adenomyosisEvery woman in menopauseEstradiol replacement therapy

progesterone (excessive breast tenderness, irregular heavy periods, etc.) then she will most likely

benefit from cyclical or nightly progesterone.

Testing

Blood tests are the best way to assess pre-treatment levels and to monitor dosing. Symptoms are

always the most important guide to dosing, but testing adds valuable additional information and can

help one decide whether to try raising or lowering the dose. For instance, when there are no symptoms

of estradiol excess, it’s possible that a patient will get more benefits with a higher dose. So often the

only way to find the optimal dose is to produce some symptoms of estradiol excess, then lower the dose

to eliminate those symptoms. I monitor patients with blood tests done approximately 12 hrs after the

application of estradiol, progesterone and testosterone. Since this time is mid-way between the daily

doses, it provides a good estimate of their 24 hr. average levels—particularly with transdermal

application. Typically I have patients begin by applying the hormones at bedtime and then have their

blood drawn in the morning. If they prefer to apply the hormones in the morning, I either have them do

an afternoon test, at least 8 hrs after application, or I have them switch to bedtime dosing for 3 nights

before the test for AM testing. AM testing is the norm for my patients as they are often taking thyroid

hormone which must be tested in the AM prior to their daily dose.

I have not found saliva testing to be useful for pre-treatment testing and it cannot be used at all to

monitor estradiol, progesterone or testosterone levels on replacement therapy. Blood testing is covered

by most persons’ insurance and so is easy to order and to obtain at low cost to the patients. Blood tests

also provide the most accurate assessment of effective hormone delivery while on replacement therapy.

Saliva testing can be accurate prior to hormone replacement, but cannot be used to monitor

transdermal steroid hormone replacement. (see Appendix 4).

For women on appropriate estradiol replacement, a serum level around 12 hrs after a dose will

typically be in the follicular-phase range, usually between 30 and 100pg/ml. This level is sufficient to

provide the health benefits of estradiol without causing symptoms of excess estradiol. Women do not

need the higher estradiol levels seen at ovulation or in the luteal phase as these are for producing

pregnancy, not for maintaining health. Progesterone levels on replacement are more difficult to

interpret. Typical progesterone levels without replacement are under 1ng/ml. Progesterone cream at

my typical dose of 100mg/ml nightly, produce low serum levels at 12 hrs (usually just 2 to 4 ng/ml).

Sublingual progesterone tablets produce serum levels that vary greatly, between 2ng/ml up to 15ng/ml

at 12 hrs.

The best serum test of any steroid hormone is the free hormone level—which indicates how much of

the hormone is free in the serum and thus able to get into the cells of the body. The vast majority of the

hormone in the serum (>95%) is not free but bound to proteins and thus not able to contact cell walls.

The amounts of these binding proteins can vary

greatly between patients naturally and due to other

factors, thus total serum levels can be quite

misleading. Only recently have free estradiol levels

become available. However, I typically order the total

estradiol because of its lower cost, as I am adjusting

the dose by symptoms anyway. I do order the free estradiol level to solve problems and in women that I

know have high SHBG levels. Oral T3 thyroid replacement, either with liothyroinine or NDT, raises SHBG

due to its first-pass effect on the liver.

Estradiol and Progesterone Restoration

Based upon the history, symptoms and test results, I decide whether estradiol and progesterone, or

progesterone alone are indicated. Improvement in or resolution of key symptoms is proof that a

deficiency existed and has been corrected. The goal, as in all hormone restoration, is to eliminate all

symptoms of hormone deficiency while producing no symptoms of hormone excess. Serum levels tested

at appropriate times are helpful, but not as sensitive or as specific to the patient as are symptoms.

replacement therapy needs to be individualized—not just the dose but also the route of delivery, time of

delivery, etc. The goal is to produce the best clinical effect in a way that is convenient for the patient. I

present the choice of hormone restoration to every patient as a trial—to see if in fact it helps eliminate

symptoms and improves their quality of life. They can decide if they want to continue the hormone. I do

of course also inform them of the health benefits of restoring the hormone and the health problems

expected with not restoring the hormone. I have learned to have patients start only one hormone at any

given time, and wait a minimum of 5 days before adding a 2nd hormone. Given the misinformation and

controversy surrounding the hormone restoration and compounding pharmacies; and given our

perverse civil liability-malpractice system and physician-oversight by state medical boards, I have every

patient sign a detailed consent form (see this under “Forms” at my website). I recommend that every

physician do the same for any hormonal therapy that is not the “standard practice” as advocated by

drug-company funded professional organizations.

There are FDA-approved progesterone and estradiol products. Estradiol comes in pills patches, gels,

and a vaginal ring. The transdermal estradiol products are acceptable, but I do not prescribe them much

Symptoms/signs of Estradiol Excess Breast/nipple tendernessVaginal spotting/bleedingFluid retentionExcessive emotionality, cryingHot flashesExcessive vaginal secretions

for several reasons. They often come in fixed low-dose formulations, adjusting the dose is not easy, and

their cost is high. Some products cost $200/mo. or more; usually the co-pays are more than a

compounded estradiol cream, which can cost as little at $10/mo. The least expensive FDA-approved

estradiol products are the generic patches, but again often the dose, even of the highest-strength patch,

is insufficient. Women also often have inadequate adherence of the patches or skin reactions to the

adhesive. Estradiol gels, unlike creams, can have a drying effect on the skin that many women do not

like. There is no FDA-approved estradiol and progesterone combination product; the combinations

products with estradiol contain a progestin instead.19 If pharmaceutical corporations really want to help

women by providing convenient and physiological BHRT, I suggest that they develop once-weekly,

subcutaneously injectable preparations containing various proportions of estradiol, progesterone, and

testosterone. This will be more convenient and will eliminate the sex hormone contamination of the

environment that occurs when people wash off hormones that were applied to their skin. I know that

women will find this acceptable as I’ve found it easy to teach men to do weekly subcutaneous injections

of long-acting testosterone cypionate and enanthate preparations.

For estradiol replacement, I typically start a woman on a compounded estradiol cream of strength

3mg/0.5ml (6mg/ml). I usually ask that it be put in a 3ml syringe designed for topical use. (See the next

chapter for a discussion of pharmacy compounding). The syringe has marks at every 0.1ml. Of course

any device to deliver the cream is fine if it allows the

woman to finely adjust the dose of the cream. If they

have been estradiol-deficient for some time, they will

be initially very sensitive to the hormone. The most

likely symptom of initial sensitivity is breast/nipple

tenderness. So I have them start with a low dose of

0.1ml (1 line) applied to face at bedtime and tell them

to increase the dose of to 0.3ml as tolerated. They can lower the dose or keep it low in order to

minimize breast tenderness. I have them add progesterone nightly after they have been on 0.2 ml of

estradiol for several days.

I have women begin by applying the estradiol cream to their face at bedtime. They can apply other

creams afterwards—which likely further increases the absorption of the estradiol. Estradiol increases

collagen formation in the body in general, and even more so where it is applied, so it helps counteract

the weakening and wrinkling of skin of the face that occurs with aging. Absorption from facial skin is also

very good, so the dose can be lower than if applied elsewhere. Some women get acne-form changes on

FDA-Approved Bioidenticals Estradiol patches (ClimaraÒ,VivelleÒ, etc.)Estradiol gel (EstrogelÒ, DivigelÒ, ElestrinÒ

Estradiol vaginal ring (FemringÒ) Progesterone capsules (PrometriumÒ)Progesterone vaginal gel (CrinoneÒ)Testosterone gel (AndrogelÒ) (not approved for women)

their face with applying the estradiol there. In which case they can apply it to the neck which also has

good absorption. If they want to apply it elsewhere—like shoulders or inner thighs, they will need higher

doses. Estradiol cream can also be applied to the genital skin—the inner labia, clitoris and vaginal

opening. It is very highly absorbed there and can produce maximal improvement in vaginal dryness and

atrophy. However, it can also promote uterine stimulation more than when applied elsewhere, and so

cause more bleeding problems. For some women, a good solution is to apply a small amount of the total

daily dose to the inner genital skin.

There is a large variation between persons in their absorption of transdermal estradiol. 20 A sufficient

dose of estradiol should definitely eliminate hot flashes and restore vaginal moisture. The dose should

be lowered if there is persistent breast fullness/tenderness or vaginal bleeding. In some women, hot

flashes can worsen with starting estradiol replacement, even though it is clearly needed. In my

experience, this is either just a temporary adjustment problem, or a sign of insufficient cortisol. First I

will try having them lower the estradiol dose, providing them with a weaker cream if needed. They can

then often gradually increase the dose to good replacement levels.

With applying any hormone to the skin, it is essential to rub it in well, until dry, and then to wash

one’s hands. It is important to avoid transfer of the hormones to other persons. For women applying

estradiol to their face, this means they should have allow a dog to lick their face overnight, nor routinely

have face-to-face contact with a child or spouse during that time. If they cannot avoid such contact, then

can apply the estradiol to the neck or elsewhere, or apply it in the AM instead and wash it off by

evening. Hormones should not be applied to elbow areas or below since the hormone entering the

circulation from these areas will spuriously increase serum tests when blood is typically draw from a

vein in the elbow area.

Relatively low levels of progesterone reduce mitoses (cell division) in the endometrium, but higher

levels are necessary to induce withdrawal bleeding and endometrial secretory transformation. So the

induction of amenorrhea with a relatively low dose of progestone is all that is needed to provide

protection against uterine cancer.21 For progesterone replacement my typical starting approach is to

use a compounded 100mg sublingual tablet at bedtime. This is a large dose for sublingual delivery and

much more effective oral Prometrium and its generics. Oral progesterone is only about 10%

bioavailable, its absorption is doubled if taken with food.22 One must work closely with a compounding

pharmacy to make sure that the tablets are pleasant to taste and dissolve in a reasonable amount of

time. Sublinguals should not be overly sweetened or flavored as this increases salivation and the amount

of hormone swallowed rather than absorbed directly in the the bloodstream through the oral mucosa.

Some of the sublingual progesterone will be swallowed and the liver will produce sedating metabolites,

but less so than with oral capsules. These metabolites have the beneficial effect of sedation and so can

improved sleep, which is a frequent problem for menopausal women. I find laboratory testing less

helpful for progesterone than with any other hormone. After the bedtime sublingual dose, serum

progesterone levels a very high—higher than youthful luteal levels—for several hours. By 12 hrs,

however, levels may be low-luteal again. This is a kind of pulse-therapy and the high-levels pulses seem

to proved the body with sufficient progesterone to last for 24hrs. Ultimately the progesterone dose has

to be adjusted by symptoms. If I’m unable to eliminate estrogen dominance symptoms by lowering the

estradiol dose—if the lower doses cause estradiol deficiency symptms to return, then I will increase the

progesterone dose or have a women insert the subligual tablets or capsules vaginally at bedtime.

Vaginal progesterone has both greater systemic effects and particularly greater effects on the uterus.

Some women have uterine conditions (e.g. submucosal fibroids, adenomyosis, polyps, etc.) that make

them very susceptible to bleeding on estradiol therapy. For many of these women, only vaginal

progesterone will allow them to replace estradiol without bleeding.

Transdermal progesterone cream can also be used. I typically prescribe 100mg/ml and have the

woman apply 1ml to the chest and breasts, abdomen, or inner thighs at bedtime. Only a small fraction

of this dose is absorbed, but it avoid the first pass effect altogether. In my experience 100mg by cream is

not as effective as 100mg subingually to control bleeding or breast tenderness. If women prefer the

cream, the dose can be increased as needed to achieve good clinical effect.

For premenopausal or perimenopausal women with early breakthrough bleeding and/or heavy

bleeding and cramping, I will always search for and correct hypothyroidism. Sufficient thyroid hormone

can normalize menses and can greatly reduce bleeding and cramping. If thyroid levels are not the

problem, I will use progesterone supplementation to prevent the build-up of the uterine lining and

thereby reduce bleeding and cramping. First, one can try the most physiological approach—taking

progesterone daily only during the luteal phase—from ovulation to just before the next period is

expected. The dose can be as little as 100mg sublingually at bedtime, or increased if needed to 100mg

twice-daily. If luteal-phase progesterone dose not work sufficiently well, she can just take the

progesterone every night and stop it when a period starts, restarting it when the bleeding has stopped.

Taking progesterone throughout the month this way has maximal anti-estradiol effects and minimizes

uterine lining build-up.

The physician can prescribe progesterone, in any dose needed, without fear of harmful effects.

Progesterone is not known to harm a woman’s health, at any dose or any serum levels. During

pregnancy, progesterone levels are many times those that are seed at their peak in the luteal phase of a

menstrual cycle. Excessive progesterone may cause some unpleasant symptoms—sedation and

gastrointestinal relaxation. Progesterone’s effect on the GI system may produce constipation or reflux.

Progesterone counteracts estradiol, so an excessive progesterone/estradiol ratio may cause estradiol

deficiency symptoms even if estradiol levels are good. In perimenopause, women can have very high

estradiol levels at times, with almost no progesterone. This produces the excessive breast tenderness

and bleeding seen in many perimenopausal women. Physicians should prescribe as much progesterone

as is needed to reduce the breast and uterine symptoms. Sufficient progesterone effect, with vaginal

delivery if needed, would prevent most hysterectomies that are performed in perimenopause for heavy

bleeding. Presently physicians are afraid to provide sufficient progesterone because of the mistaken

belief that progesterone has the same deleterious effects as many progestins do. (See next chapter.)

To Bleed or not to Bleed

If women want to continue to menstruate after menopause., they can with the right cyclical use of

estradiol and progesterone. Estradiol must be taken alone for 2 weeks, then progesterone added for 2

weeks—in a sufficient dose to change the uterine lining and prevent bleeding until the progesterone is

stopped. This typically requires higher estradiol doses and twice-daily progesterone dosing for the last

two weeks. The estradiol dose can be the same each day, but can also be lower in the first two weeks

and higher in the second two weeks to mimic a normal cycle and pervent breakthrough bleeding. At the

end of the 4 week cycle, stopping the progesterone and/or lowering the estradiol dose causes sloughing

of the lining.

However, this is not a true menstrual cycle but only an imitation of a cycle. It is just a building up and

the sloughing off of the uterine lining. As mentioned early, the purpose of the menstrual cycle is

reproduction first, a women’s health second. In my opinion, a woman needs only a certain daily levels of

estradiol and progesterone for her health needs. When estradiol and progesterone are taken together

daily and in proper balance, there is little build-up of the uterine lining, and so no need to have a period

to shed the lining. The one potential benefit of cycling the hormones is that is could induce a sloughing

of the breast duct epithelium23 which may have a further anti-cancer effect. This should be studied

further. I’m not yet convinced that this effects occurs with cyclic estradiol/progesterone therapy, or that

that it is significant enough to justify the inconvenience of bleeding for the rest of a woman’s life. Most

women do not want to have bleeding after menopause.

Troubleshooting Estradiol-Progesterone Therapy

It is important to remember, again, that bioidentical hormones have the expected effects in the

human body. They have no side effects. Understanding this allows the physician to solve and fix

problems that arise during BHRT. Any negative symptoms or problems with estradiol-progesterone

restoration must be due either:

1. Excessive or inadequate dosing2. Wrong method of delivery3. An imbalance with other hormones4. Sensitivity to an inert component of the hormone product5. An underlying disease or disorder that is worsened by a hormone

For instance, women with underlying breast or uterine pathologies may not tolerate the stimulatory

effect of any estradiol restoration. The inability to tolerate any estradiol or progesterone may be due to

cortisol deficiency. With any symptoms that are possibly due to excessive estradiol effect in the breasts

or uterus or elsewhere the first intervention should be to lower the estradiol dose. If a lower dose

produced estradiol-deficiency symptoms, then one should raise the dose and increase the delivery of

progesterone. It taking oral progesterone, increase the dose, switch to sublingual at the same dose, or

take the progesterone vaginally.

Bleeding and Uterine Cancer Surveillance

Spotting and bleeding are not uncommon on replacement therapy and I tell every woman with a

uterus that it still works and bleeding is possible, but will not persist with proper dose adjustment. The

primary concern of any gynecologist is to rule out uterine cancer in any women with bleeding after

menopause. Standard practice guidelines call for a transvaginal ultrasound and uterine biopsy for any

bleeding after menopause. This does not apply to a woman taking hormones since they are not

estradiol-progesterone deficient. Such procedures are warranted only if a women spots/bleeds with any

doses of estradiol and progesterone or if she continues to bleed after stopping the hormones for a

couple months. Likewise, gynecological guidelines call for a uterine biopsy if a trans-vaginal ultrasound

shows that the uterine lining is >5mm in thickness. This again only applies to women who are estradiol-

progesterone deficient in menopause. The uterine lining is much thicker than this cyclically in

menstruating women, and there is no evidence to suggest that this guideline should be applied to

women on EP therapy as they have premenopausal progesterone levels.

Bleeding can occur for several reasons. A women who has only recently stopped having menstrual

bleeding for a few months may have a thickened uterine lining due to incomplete shedding with the last

bleed or due to estradiol production since the last bleed. When she takes progesterone, the uterine

lining is destabilized and sloughs off. This is a therapeutic result. Bleeding that occurs after some weeks

on EP therapy may still be due to initial uterine lining thickness. I will typically have the woman stop

both hormones to encourage a complete shedding of the lining. When all bleeding has stopped for a day

or two, I have her restart the estradiol and progesterone at the same doses. If bleeding recurrs, I have

her stop the hormones again, and then restart with a lower estradiol dose (less by 0.1ml). If she feels

worse on the lower estradiol dose (has symptoms of estradiol deficiency), I’ll have her raise the dose to

the previous level and change the progesterone dose/delivery to provide more progesterone effect in

the uterus. Occasionally a woman who has had no bleeding for many months

Testosterone Replacement in Women

How much testosterone, what levels and effects, are best for a woman? That is a complicated and

very personal question. Testosterone acts on a continuum from lower to higher levels. One study found

that the serum testosterone level in women with no acne, hirsutism, or menstrual dysfunction was only 14.1

pg/ml. Higher levels were found with increasing hirsutism and menstrual dysfunction. The authors suggested an

upper limit of 28ng/dl to exclude “hyperandrogenemia (usual range 0-95ng/dL).24 More testosterone will

increase hairiness in women and in men, the question for each woman, however, is at what level they

will have the best compromise between the benefits of testosterone supplementation and the negative

effects. Excessive testosterone for a given woman can cause excessive dark facial hair, oily skin, body

odor, frontal scalp hair loss, and acne. Higher levels can cause deepening of the voice and clitormegaly.

How a woman responds to higher testosterone varies remarkably. Some women will experience

excessive facial hair or acne with any attempt to increase their testosterone level, others can live with

well-above-range levels with no hyperandrogenic symptoms at all. What is consistent is that the higher a

women’s testosterone levels are, the greater her energy, physical stamina, muscle strength and libido.

Testosterone Replacement

I start with 2mg/0.2ml cream, 0.1ml (1 line) applied inner labia at bedtime.

Best absorption, improved libido and vaginal moisture

If excess acne or facial hair lower dose.

If not tolerated labially, use higher strength/amount to inner thighs or back of knees (no local hair

growth)

12 hr. serum total testosterone usually high, but free testosterone is half of upper range.

DHT may be high—not routinely tested

Beyond Normality: Hormonal Solutions for Women

The restoration of hormones lost in menopause is itself a choice to go against Nature and its

compromise for female reproduction. There is more that can be done to improve women’s lives, in

accordance with their choices regarding their well-being, ferility and functionality.

I believe that women should have endocrine choice—I think that most would agree. Nature has given

them a hormonal system optimized by the requirements of our species to produce and feed infants and

then provide care for children. We live in a different world now. Women want to be equal to men in

most important ways—but they don’t have the hormonal system for it. They have far lower

testosterone levels than men—1/10th those of men. Because of this they are at a serious disadvantage

when they compete with men in the workplace. Their lower muscle strength practically excludes them

from many jobs (construction, auto repair, plumbing, lumberjacking, etc.). Even if the job does not

require much physical strength, their lower testosterone levels also leave them with lower mental and

emotional stamina, making it harder for them to handle sustained stress, including the stress of white-

collar jobs. (Lower cortisol levels also play a role here as discussed). Testosterone optimization can help

them live the kind of lives they want to life. Some may want and tolerate free testosterone levels above

the female reference range (0-2.2pg/ml), but below optimal the male range (18-26pg/ml). In a study of

weekly testosterone injections in oophorectimized women, doses that produced trough free

testosterone levels well above the reference ranges, women had improved vitality, muscle strength and

sexual function with little unwanted hyperandrogenic effects. The highest dose of 25mg/week produced

trough free testosterone levels of 39pg/ml, well above the upper limit for women of 7.2pg/ml, but at

the bottom of the male ref. range of 35-155pg/ml). If women desire the benefits of higher-than-natural

testosterone levels, they should be allowed that choice. They can decide what androgenic changes they

are willing to tolerate for the benefits they get with higher testosterone levels. Sufficient testosterone

alone my suppress their menstrual cycle, further improving their functionality at all times and treating

serious premenstrual disorders.

Testosterone appears safe at any dose/level in women. Even giving women male levels of

testosterone with injections (female-to-male transsexuals) is not associated with any increase mortality,

breast cancer, vascular disease, or other major health problems. 25 Male levels of testosterone suppress

ovulation and reduce proliferation in the breasts and endometrium,26 suggesting a possible protective effect

against cancer in these organs. No increase in breast cancer or mortality has been seen in M-to-F

transsexuals.27

Hormonal therapy might help prevent breast cancer later in life. Since pregnancy protects against

breast cancer, women who are not planning on pregnancy for many years after menarche could be

offered high doses of estradiol and progesterone for a few months (a pseudopregnancy).28

Appendix 1. Estriol, OTC Progesterone Cream, Saliva Testing, and the Wiley

Protocol

Due to the advice of Dr. Jonathan Wright, a pioneer in bioidentical hormone replacement and natural

scientific medicine, prescribers often include estriol and estrone in compounded bioidentical hormone

therapy. Based upon a study performed in his own laboratory, Dr. Wright asserted that premenopausal

women had very high estriol levels—between 200 and 2400 pm/ml—much higher than their estradiol

levels.29,30 However, subsequent studies have contradicted his assertion, finding estriol levels of only 7 to

11pg/ml in menstruating women, and of 6pg/ml in postmenopausal women.31,32 Compares the levels of

this weak estrogn with the typical estradiol levels of 30 to 200pg/ml at various times in the menstrual

cycle.

The combination of estradiol and estriol is called "Biest". It typically contains estradiol and estriol in a

20:80 ratio. When estrone is added it is called “Triest”. Women on these preparations often receive too

little estradiol, and thus have persisting symptoms of estradiol deficiency. Practitioners who attend

weekend BHRT are often taught to prescribe Biest and to adjust the estradiol dose using saliva testing.

This leads to gross underdosing (See Appendix 3). Estriol levels are rarely measured either before

starting therapy or during therapy. How much of it is absorbed transdermally is unknown, likely it is less

well-absorbed than estradiol due to its three hydroxyl groups. Many practitioners still routinely

prescribe estriol along with estradiol. He performed study showing that In fact estriol exists in very low

concentrations. It is just a weak metabolite of estradiol. Its levels are very high only in pregnancy when

the placenta produces it from DHEA sulfate. Estriol binds preferentially to the second estrogen (ERbeta).

ERbeta may function as a tumor suppressor.33 Estriol’s estrogenic activity at estradiol receptors is a small

fraction of that of estradiol, possibly due to its more rapid dissociation from receptors.34 Therefore, in a

state of complete estradiol deficiency, estriol supplementation will produce estrogenic effects. However,

when estradiol is supplemented to sufficient levels, estriol may act more like and estradiol-blocker—

inhabiting estradiol receptors but stimulating them much less than estradiol would. Vaginal estriol, for

instance, is very effective at reversing the urogenital atrophy caused by estradiol deficiency. 35 Oral

estriol, 2mg/day, given to elderly women, increased their estradiol levels and improved endothelial

function and bone density.36

The evidence we have currently suggests that estradiol replacement is all that is needed.

Transdermal estradiol is naturally metabolized into estriol and estrone and restores them to normal

follicular levels. For me to be convinced that every woman should pay the additional cost of adding

estriol to estradiol, I would need to see evidence showing that 1. That the metabolism of estradiol on

estradiol-only replacement therapy does not produce normal follicular phase estriol levels. 2. That

transdermal estriol does restore follicular phase estriol levels, and 3. That estriol supplementations

improves symptoms or long-term health outcomes.

Over-the-counter (OTC) non-prescription 2% progesterone cream is bioidentical and is beneficial to

women in perimenopause and menopause. Percutaneous progesterone has a much greater effect upon

the endometrial lining than indicated by serum progesterone levels.37 I recommend OTC progesterone

cream for every woman in perimenopause and for every woman in menopause who is not taking

estradiol. OTC creams at the typical doses of 20 to 40mg applied daily, do not provide sufficient

progesterone for women who are replacing estradiol to optimal levels.38,39 An adequate dose should be

80 to 100mg or more applied daily. A cream with a higher progesterone concentration requires a

prescription.

Saliva tests may be accurate for assessing sex hormone levels before supplementation, although

some researchers found little correlation between saliva and serum estradiol40 and progesterone41

levels. However, saliva tests grossly overreact to even minimal amounts of hormones applied to the skin. 42,43 In general, hormone test results require careful interpretation when the hormone is being restored.

The delivery methodand the time from the last dose greatly effect the result. but with the application of

any steroid hormone to the skin, including sublingual and vaginal application, saliva levels rise

excessively—many times higher than levels seen on a blood test and as indicated by symptoms. 44 This is

due to the unusual soaking of red-blood cell membranes with the fat-soluble steroid hormone. Red

blood cells must deform to pass through the smallest capillaries. In areas where the hormone is applied,

these capillary walls are soaked with hormone, and so it is taken up into the red-blood cells walls.

Steroid hormones in the red blood cell membrane can be delivered to the tissues.45,46 For some reason,

this causes much more hormone to get into the saliva. Blood tests almost always measure the hormone

in the watery serum and not what is incorporated into blood cells. So blood tests can underestimate

delivery of transdermal steroids to the tissues, while saliva tests grossly overestimate it.47 This

discrepancy is greatest with progesterone because it is the most fat-soluble of the steroid hormones. For

instance, practitioners who dosetransdermal hormones to produce normal saliva levels are underdosing

their patients. On theother hand, serum blood tests (with the red cells removed) can underestimate the

actual blooddelivery of transdermal progesterone and estradiol, causing the practitioner to overdose

thepatient. Studies have shown that 80mg/day of progesterone in a cream produces significantwhole-

blood progesterone levels, equal to 200mg of Prometrium, but dose not produce muchincrease in serum

progesterone levels (Hermann, 2005). Most labs test only serumprogesterone and this has caused

doctors to erroneously conclude that progesterone creamshave no effect.

The Wiley Protocol is a type of compounded BHRT endorsed by T. S. Wiley. It uses transdermal

estradiol and progesterone, in varying amounts throughout the cycle, to produce both serum levels of

estradiol and progesterone levels that are identical do those of a menstruating young woman. As

mentioned above, normal menstrual cycle hormone levels are for producing pregnancy, not for

optimizing a woman’s health. So the primary motivation for this protocal is flawed. However there is a

bigger problem. Serum hormone levels can underestimate the total hormone delivery of transdermal

steroid hormones. This is especially for true for progesterone.48 Women on the Wiley Protocol are thus

grossly overdosed, both with estradiol and progesterone, producing a state resembling pregnancy.

1 Buster JE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother. 2010 Jun;11(9):1489-99.

2 Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal

estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A

randomized controlled trial. Arterioscler Thromb Vasc Biol 1997 Nov;17(11):3071-8

3 Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008 May 31;336(7655):1227-31.

4 Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007 Feb 20;115(7):840-5.

5 Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008 Nov;29(21):2660-8.

6 Slater CC, Zhang C, Hodis HN, Mack WJ, Boostanfar R, Shoupe D, Paulson RJ, Stanczyk FZ.Comparison of estrogen and androgen levels after oral estrogen replacement therapy.J Reprod Med. 2001 Dec;46(12):1052-6.

7 Basbug M, Aygen E, Tayyar M, Muhtaroglu S, Demir I, Okten S. Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women. Eur J Obstet Gynecol Reprod Biol. 1997 Jun;73(2):149-52.

8 Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007 Nov-Dec;14(6):985-94.

9 Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D; SARAH Investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1671-6.

10 Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies

on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal

women. Menopause. 2006 Jul-Aug;13(4):643-50.

11 Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 2001 Jun 19;103(24):2903-8.

12 Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stanczyk FZ, Lobo RA. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril. 1994 Dec;62(6):1176-80.

13 Racine A, Bijon A, Fournier A, Mesrine S, Clavel-Chapelon F, Carbonnel F, Boutron-Ruault MC. Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. CMAJ. 2013 Apr 16;185(7):555-61. doi: 10.1503/cmaj.121490.

14 Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008 Jul 10;337:a386. doi: 10.1136/bmj.a386.

15 Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen

replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-

binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):374-81.

16 Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). Fertil Steril. 2000 Mar;73(3):516-21.

17 Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments.Hum Reprod Update. 2000 Mar-Apr;6(2):139-48.

18 Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol 2005;45:614-619.19 Harvard Women’s Health Watch, Sept. 2011, http://www.health.harvard.edu/newsletters/Harvard_Womens_Health_Watch/2011/September/fda-approved-bioidentical-hormones-for-menopausal-symptoms

20 Kraemer GR, Kraemer RR, Ogden BW, Kilpatrick RE, Gimpel TL, Castracane VD. Variability of serum

estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the

effect on androgens and sex hormone binding globulin. Fertil Steril. 2003 Mar;79(3):534-42.

21 Moyer DL, de Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril. 1993 May;59(5):992-7.

22 Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993 Jul;60(1):26-33.

23 Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol. 1986 Jun;10(6):382-93.

24 Ayala C, Steinberger E, Smith KD, Rodriguez-Rigau LJ, Petak SM. Serum testosterone levels and reference ranges in reproductive-age women. Endocr Pract. 1999 Nov-Dec;5(6):322-9

25 Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med. 2010 Nov;7(11):3758-64.

26 Grynberg M, Fanchin R, Dubost G, Colau JC, Brémont-Weil C, Frydman R, Ayoubi JM. Histology of

genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual

population. Reprod Biomed Online. 2010 Apr;20(4):553-8.

27 van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997 Sep;47(3):337-42.

28 Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2520-5.29 Wright JV, Schliesman B, Robinson L. Comparative measurements of serum estriol, estradiol, and estrone in non-pregnant, premenopausal women; a preliminary investigation. Altern Med Rev. 1999 Aug;4(4):266-70.30 Wright, J. V., Bio-Identical Steroid Hormone Replacement, Selected Observations from 23 Years ofClinical and Laboratory Practice, Ann. N.Y. Acad. Sci. 1057: 506–524 (2005).

31 Longcope C. Estriol production and metabolism in normal women. J Steroid Biochem. 1984 Apr;20(4B):959-62.

32 Rotti K, Stevens J, Watson D, Longcope C. Estriol concentrations in plasma of normal, non-pregnant

women. Steroids. 1975 Jun;25(6):807-16.33 Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004 Sep;11(3):537-51.

34 Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977 Jun;37(6):1901-7.

35 Dessole S, Rubattu G, Ambrosini G et al.: Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11(1), 49-56 (2004).

36 Hayashi T, Ito I, Kano H, Endo H, Iguchi A. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. J Gerontol A Biol Sci Med Sci. 2000 Apr;55(4):B183-90; discussion B191-3.

37 Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause. 2005 Mar;12(2):232-7.

38 Wren BG, McFarland K, Edwards L: Micronised transdermal progesterone and endometrial response. Lancet 354(9188), 1447-1448 (1999).39 Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG. 2005 Oct;112(10):1402-6.40 Tivis LJ, Richardson MD, Peddi E, Arjmandi B. Saliva versus serum estradiol: implications for research studies using postmenopausal women.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):727-32.

41 Herges H, Klinger W, Gethmann U, Knuppen R. Determining progesterone in saliva Zentralbl Gynakol.

1992;114(11):533-8.

42 Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas. 2002 Jan 30;41(1):1-6.

43 O'Leary P, Feddema P, Chan K, Taranto M, Smith M, Evans S. Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre-and postmenopausal women.Clin Endocrinol (Oxf). 2000 Nov;53(5):615-20.44 Lewis JG, McGill H, Patton VM, Elder PA: Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 41(1), 1-6 (2002).

45 Hiramatsu R, Nisula BC. Uptake of erythrocyte-associated component of blood testosterone and corticosterone to rat brain. J Steroid Biochem Mol Biol. 1991 Mar;38(3):383-7.

46 Koefoed P, Brahm The permeability of the human red cell membrane to steroid sex hormones.

J.Biochim Biophys Acta. 1994 Oct 12;1195(1):55-62.

47 Vimpeli T, Tinkanen H, Huhtala H, Ronnberg L, Kujansuu E., Salivary and serum progesterone concentrations during two luteal support regimens used in in vitro fertilization treatment. Fertil Steril. 2001 Oct;76(4):847-8.

48 Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol 2005;45:614-619.